Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]-F0502B
- Development stage
- Unknown
- Lead developer
- Shanghai Braegen Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]-F0502B is a fluorine-18 labeled positron emission tomography (PET) tracer developed by Shanghai Braegen Pharmaceuticals for the early diagnosis of Parkinson's disease. The agent is designed to selectively bind to alpha-synuclein aggregates, which are the primary pathological hallmark of synucleinopathies, including Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). By enabling the non-invasive visualization of these aggregates in the brain, [18F]-F0502B serves as a diagnostic tool to improve diagnostic accuracy and monitor disease progression. It is currently in the preclinical stage, with investigator-initiated clinical studies ongoing to evaluate its performance in human subjects.
- Other names
- [18F]-F0502B[18F]F0502B
02
Targets
Amyloid-beta aggregate (N-terminal epitope)aggregated α-syn (Alpha-synuclein (α-syn))Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on [18F]-F0502B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]-F0502B.